-
Data on half of study patients after 6-month review to be presented to Australian cancer conference Nov 2019
-
Data suggests major anti-cancer effect of Veyonda/DARRT treatment regimen in late-stage prostate cancer
-
80% of late-stage prostate cancer patients (reviewed to date) showing no disease progression after 6-months
-
55% showing clinically significant reduction in pain at 6-months
-
DARRT-2 being planned for commencement in 2020
Sydney, 21 October 2019: Noxopharm (ASX: NOX) provides an update on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late- stage, progressive and metastatic and who have limited survival prospects.
This is ahead of a presentation by the Company of clinical data to the Clinical Oncology Society of Australia Annual Scientific Meeting, 12-14 November 2019.
For further information please download the attached PDF:
Download this document
